Fate Therapeutics’ long-standing Chief Scientific Officer Daniel Shoemaker, Ph.D., will be leaving the cell therapy biotech this summer.

Antibody biotech Lassen Therapeutics is joining forces with Cedars Sinai Medical Center to study the role of the cytokine IL-11 in lung fibrosis and whether blocking IL-11 signaling could be useful in treating this bucket of diseases in preclinical models.

Frequency Therapeutics is going back to the drawing board. After showing promise in phase 1, four dosing regimens of its hearing loss treatment did no better than placebo in a phase 2a study. The company will press ahead with a single-dose regimen and is waiting on final results from this study as well as readouts from two more phase 1b studies to plot its next steps.

After raising $45 million last summer to expand its virtual health research platforms—and supplement them with follow-up digital care and personal interventions—Evidation Health has now scored another $153 million to rapidly accelerate its work.

The two largest dialysis providers in the U.S. are teaming up to pursue a business proposition that might seem antithetical in nearly any other field or at any other time outside of a worldwide pandemic. They aim to help get patients out of their respective clinics and have them access treatment from inside their own homes.

Johnson & Johnson Vision has received its first global approval for a contact lens infused with an antihistamine, designed to help curb the itchiness that comes with eye allergies.

People who suffer heart attacks frequently progress to chronic heart failure due to scarring and inflammation that hampers heart function. Researchers at Baylor College of Medicine have early evidence that a small-molecule drug may be able to stimulate healing after heart attack in a way that prevents that progression to heart failure.

Odonate Therapeutics is ending development of its oral chemotherapy drug and closing up shop after the FDA deemed the drug’s clinical data “unlikely to support FDA approval.” As it winds down its operations, the company will work with clinical sites to switch patients participating in its clinical trials to alternative treatments, the company said in a statement Monday.

Could native, exhausted and no-longer-functioning natural killer cells (NK cells) in cancer patients be rescued and revived by a novel, off-the-shelf immuno-oncology therapeutic that also happens to be a pervasive serial cancer killer?

BridgeBio Pharma’s treatment for a rare hormonal disorder helped patients reach normal levels of that hormone as well as of calcium, phosphorus and magnesium in their blood, early phase 2 data show. The company’s next stop will be a meeting with regulators ahead of a phase 3 study to figure out the treatment’s path to patients.